Order Article Reprints

Revilla G, Al Qtaish N, Caruana P, Sainz-Ramos M, Lopez-Mendez T, Rodriguez F, Paez-Espinosa V, Li C, Vallverdú NF, Edwards M, et al. Lenvatinib-Loaded Poly(lactic-co-glycolic acid) Nanoparticles with Epidermal Growth Factor Receptor Antibody Conjugation as a Preclinical Approach to Therapeutically Improve Thyroid Cancer with Aggressive Behavior. Biomolecules. 2023; 13(11):1647. https://doi.org/10.3390/biom13111647

Revilla, Giovanna, Nuseibah Al Qtaish, Pablo Caruana, Myriam Sainz-Ramos, Tania Lopez-Mendez, Francisco Rodriguez, Verónica Paez-Espinosa, Changda Li, Núria Fucui Vallverdú, Maria Edwards, and et al. 2023. "Lenvatinib-Loaded Poly(lactic-co-glycolic acid) Nanoparticles with Epidermal Growth Factor Receptor Antibody Conjugation as a Preclinical Approach to Therapeutically Improve Thyroid Cancer with Aggressive Behavior" Biomolecules 13, no. 11: 1647. https://doi.org/10.3390/biom13111647

Revilla, G., Al Qtaish, N., Caruana, P., Sainz-Ramos, M., Lopez-Mendez, T., Rodriguez, F., Paez-Espinosa, V., Li, C., Vallverdú, N. F., Edwards, M., Moral, A., Pérez, J. I., Escolà-Gil, J. C., Pedraz, J. L., Gallego, I., Corcoy, R., Céspedes, M. V., Puras, G., & Mato, E. (2023). Lenvatinib-Loaded Poly(lactic-co-glycolic acid) Nanoparticles with Epidermal Growth Factor Receptor Antibody Conjugation as a Preclinical Approach to Therapeutically Improve Thyroid Cancer with Aggressive Behavior. Biomolecules, 13(11), 1647. https://doi.org/10.3390/biom13111647